|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Abstract # | Title | Word Count | #Words (Verified by WordNet) | #Medical Words  (Verified by Bioportal / BioNLP)  All (Gene/Species/etc) |
| 1 | Subgroup Survival Analysis In Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT. | 52 | body, radiation, therapy, increased, toxicity, early, stage, cell, lung, cancer, a, tumor, within, proximal, bronchial, tree, death, as, it, peripheral, | null |
| 2 | The effect of melatonin on Superoxide dismutase and Glutathione peroxidase activity, and Malondialdehyde levels in the targeted and the non-targeted lung and heart tissues after irradiation in xenograft mice colon cancer. | 103 | damage, also, do, not, receive, direct, irradiation, through, a, phenomenon, bystander, as, a, potent, antioxidant, anti-inflammatory, agent, known, protection, normal, some, have, may, have, some, complete, remain, it, can, act, aim, study, evaluate, effect, melatonin, on, oxidative, damage, by, direct, irradiation, bystander, effects, on, lung, heart, tissue, after, xenograft, colon, cancer, irradiation, in, | null |
| 3 | The main causes of death contributing to absolute and relative socio-economic inequality in Italy. | 42 | inequality, become, a, priority, many, especially, after, financial, study, at, detecting, death, inequality, in, relative, absolute, terms, in, | null |
| 4 | 30-year trends in asthma and the trends in relation to hospitalization and mortality. | 25 | present, study, in, prevalence, asthma, past, three, associate, hospitalization, mortality, same, | asthma Disease, Death Disease, women Species, asthmatic Disease, lung cancer Disease, |
| 5 | Hyper expression of MTBP may be an adverse signal for the survival of some malignant tumors: A data-based analysis and clinical observation. | 234 | explore, relationship, between, mouse, double, minute, 2, binding, protein, prognosis, cancer, a, a, clinical, observation, about, lung, adenocarcinoma, taken, verify, result, data, all, data, in, order, make, a, conclusion, about, relationship, between, prognosis, cancer, collected, lung, cancer, information, verify, data, analysis, overall, curve, 6, eligible, data, in, curve, result, in, risk, hazard, while, stratification, independently, in, 2, similar, be, in, other, 5, data, tissue, lung, adenocarcinoma, collected, expression, rate, in, adenocarcinoma, expression, significantly, worse, prognosis, control, survival, clearly, separated, each, other, expression, maybe, an, adverse, event, survival, some, cancer, especially, in, kidney, lung, cancer, verified, in, lung, cancer, | MTBP Gene, malignant tumors Disease, mouse Species, cancer Disease, patients Species, lung adenocarcinoma Disease, lung cancer Disease, GSE30219 Chemical, adenocarcinoma Disease, glioblastoma Disease, kidney cancer Disease |
| 6 | Early death in Danish stage I lung cancer patients: a population-based case study. | 105 | stage, at, diagnosis, most, significant, prognostic, marker, survival, rates, as, main, a, case, study, lung, cancer, who, considered, curative, therapy, then, within, after, diagnosis, identified, in, medical, used, retrieve, treatment, details, cause, death, identify, describe, in, terms, treatment, modality, at, risk, an, adverse, short-term, | Death Disease, stage I lung cancer Disease, patients Species, cancer Disease, c-stage I lung cancer Disease, CoD Gene, male Species, lung cancer Disease |
| 7 | Metal dyshomeostasis based biomarkers of lung cancer using human biofluids. | 368 | cancer, one, most, common, in, world, it, well, known, trace, elements, play, important, in, carcinogenic, process, activating, enzymatic, in, usually, participate, as, cross-sectional, study, on, 48, lung, cancer, 39, men, 31, aged, years, between, elements, have, included, in, some, considered, toxic, while, are, essential, have, analyzed, by, in, urine, first, time, in, lavage, fluid, order, understand, involvement, in, an, analytical, approach, based, on, precipitation, fractionation, high, molecular, mass, low, molecular, mass, metal, in, order, distinguish, between, metal, species, affect, biological, activity, toxicological, potential, by, analysis, by, applied, first, time, urine, lung, cancer, in, order, get, molecule, can, be, used, as, altered, metabolic, such, as, oxidative, stress, have, demonstrated, several, are, good, are, related, labile, low, molecular, mass, or, in, form, in, in, described, first, other, metal, are, using, metal, between, elements, be, important, lung, cancer, in, serum, urine, in, lung, several, are, correlated, also, existence, an, interconnected, homeostasis, in, lung, | Metal dyshomeostasis Disease, lung cancer Disease, human Species, LC Disease, cancer-related deaths Disease, patients Species, men Species, women Species, Cr Chemical, Mn Chemical, Fe Chemical, Cu Chemical, Zn Chemical, Se Chemical, Mo Chemical, Cd Chemical, Pb Chemical, MS Disease, non-denaturing precipitation of proteins Gene, NDPP Gene, V Chemical |
| 8 | Understanding the evolving phenotype of vascular complications in telomere biology disorders. | 98 | such, as, bleeding, due, gastrointestinal, pulmonary, arteriovenous, retinal, vessel, are, being, reported, in, telomere, biology, more, frequently, previously, international, clinical, care, consortium, family, support, group, held, a, workshop, on, vascular, in, at, in, basic, current, data, on, vascular, underlying, biology, developed, new, address, etiology, clinical, management, vascular, in, | Vascular complications Disease, telomere biology disorders Disease, bleeding Disease, gastrointestinal telangiectatic anomalies Disease, pulmonary arteriovenous malformations Disease, hepatopulmonary syndrome Disease, retinal vessel abnormalities Disease, patients Species, TBDs Disease, vascular abnormalities Disease, Cancer Disease |
| 9 | Advanced imaging in pulmonary hypertension: emerging techniques and applications. | 172 | hypertension, a, disorder, defined, by, an, increase, in, pulmonary, arterial, pressure, can, occur, in, multiple, clinical, a, negative, impact, on, exercise, capacity, quality, high, mortality, particularly, in, pulmonary, arterial, imaging, play, an, important, role, in, presence, noninvasive, pulmonary, pressure, group, a, possibly, underlying, prognostic, information, response, tomography, are, an, integral, part, routine, suspected, according, current, across, innovative, new, in, field, such, as, flow, magnetic, resonance, imaging, extracellular, volume, fraction, perfusion, ventilation, positron, emission, tomography, are, review, advanced, emerging, imaging, in, prognostic, evaluation, follow-up, | null |
| 10 | Identification of a novel anoikis signalling pathway using the fungal virulence factor gliotoxin. | 149 | a, form, apoptosis, induced, by, cell, inactivation, a, major, role, in, process, but, exact, pathway, identify, an, pathway, using, a, virulence, factor, fungus, invasive, aspergillosis, in, binding, extracellular, matrix, by, in, binding, a, focal, adhesion, kinase, inhibited, in, activation, activation, then, in, suspension, or, lacking, surface, expression, are, insensitive, but, are, sensitised, attachment, or, same, pathway, by, inhibition, or, can, target, induce, on, lung, epithelial, | fungal Species, Aspergillus fumigatus Species, invasive aspergillosis Disease, humans Species, cysteines Chemical, Cilengitide Chemical |

Abstract 1

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 20 | body, radiation, therapy, SBRT, toxicity, stage, cell, lung, cancer, NSCLC, patients, tumor, cm, tree, PBT, death, patients, GTV-proximity, PBT, tumors |
| POS:Verb | 8 | has, been, associated, increased, delivered, investigated, relates, compared, |
| NER : Name | 0 |  |
| Triplet | 86 | Seen below |
|  |  |  |

[(Lung cancer,is,leading cause,1.0), (Lung cancer,is leading cause of,cancer-related death,1.0), (Lung cancer,is cause of,cancer-related death,1.0), (Lung cancer,is leading cause of,death,1.0), (Lung cancer,is cause of,death,1.0), (Lung cancer,is,cause,1.0)]

[(cigarette smoking,is,primary cause,1.0), (cigarette smoking,is,cause,1.0), (cigarette smoking,is cause of,malignancy,1.0), (risk,differs across,racial/ethnic groups,1.0), (risk,differs,cause of malignancy,1.0), (risk,differs,primary cause,1.0), (risk,differs,primary cause of malignancy,1.0), (risk,differs across,groups,1.0), (cigarette smoking,is primary cause of,malignancy,1.0), (risk,differs,cause,1.0)]

[(smoked Hawaiians,are at,risk,1.0), (Hawaiians,are at,greater risk,1.0), (smoked Hawaiians,are at,greater risk,1.0), (Hawaiians,are at,risk,1.0), (Hawaiians,compared to,whites,0.6726029514081513), (smoked Hawaiians,compared to,whites,0.6726029514081513)]

[(common blood epigenetic modification,associated with,smoking status,1.0), (CpG sites,methylation of is,most common blood epigenetic modification associated,1.0), (DNA methylation,is,most common blood epigenetic modification,1.0), (DNA methylation,is,most common blood epigenetic modification associated,1.0), (specific CpG sites,methylation of is,common blood epigenetic modification associated with smoking status,1.0), (DNA methylation,is,common blood modification associated with smoking status,1.0), (specific CpG sites,methylation of is,common blood epigenetic modification,1.0), (specific CpG sites,methylation of is,blood modification,1.0), (CpG sites,methylation of is,common blood modification associated,1.0), (specific CpG sites,methylation of is,blood modification associated with smoking status,1.0), (DNA methylation,is,common blood modification associated,1.0), (specific CpG sites,methylation of is,blood epigenetic modification associated with smoking status,1.0), (common blood modification,associated with,smoking status,1.0), (DNA methylation,is,blood epigenetic modification associated with smoking status,1.0), (DNA methylation,is,blood epigenetic modification associated,1.0), (CpG sites,methylation of is,blood modification,1.0), (DNA methylation,is,common blood epigenetic modification associated with smoking status,1.0), (DNA methylation,is,common blood epigenetic modification associated,1.0), (CpG sites,methylation of is,common blood epigenetic modification,1.0), (blood modification,associated with,smoking status,1.0), (specific CpG sites,methylation of is,most common blood modification associated,1.0), (CpG sites,methylation of is,most common blood modification associated with smoking status,1.0), (specific CpG sites,methylation of is,common blood epigenetic modification associated,1.0), (specific CpG sites,methylation of is,blood epigenetic modification associated,1.0), (specific CpG sites,methylation of is,most common blood modification,1.0), (DNA methylation,is,most common blood epigenetic modification associated with smoking status,1.0), (CpG sites,methylation of is,most common blood modification associated,1.0), (DNA methylation,is,blood modification,1.0), (CpG sites,methylation of is,blood epigenetic modification associated,1.0), (CpG sites,methylation of is,most common blood epigenetic modification,1.0), (CpG sites,methylation of is,common blood epigenetic modification associated with smoking status,1.0), (CpG sites,methylation of is,most common blood epigenetic modification associated with smoking status,1.0), (CpG sites,methylation of is,blood epigenetic modification associated with smoking status,1.0), (specific CpG sites,methylation of is,most common blood epigenetic modification,1.0), (specific CpG sites,methylation of is,most common blood modification associated with smoking status,1.0), (CpG sites,methylation of is,most common blood modification,1.0), (CpG sites,methylation of is,common blood modification,1.0), (specific CpG sites,methylation of is,common blood modification,1.0), (DNA methylation,is,common blood epigenetic modification,1.0), (CpG sites,methylation of is,common blood modification associated with smoking status,1.0), (DNA methylation,is,common blood modification,1.0), (specific CpG sites,methylation of is,common blood modification associated,1.0), (specific CpG sites,methylation of is,most common blood epigenetic modification associated,1.0), (DNA methylation,is,most common blood modification associated,1.0), (CpG sites,methylation of is,common blood epigenetic modification associated,1.0), (specific CpG sites,methylation of is,common blood modification associated with smoking status,1.0), (blood epigenetic modification,associated with,smoking status,1.0), (CpG sites,methylation of is,blood modification associated with smoking status,1.0), (DNA methylation,is,most common blood modification,1.0), (specific CpG sites,methylation of is,most common blood epigenetic modification associated with smoking status,1.0), (DNA methylation,is,blood modification associated,1.0), (DNA methylation,is,blood modification associated with smoking status,1.0), (CpG sites,methylation of is,blood epigenetic modification,1.0), (DNA methylation,is,most common blood modification associated with smoking status,1.0), (specific CpG sites,methylation of is,blood epigenetic modification,1.0), (DNA methylation,is,blood epigenetic modification,1.0), (specific CpG sites,methylation of is,blood modification associated,1.0), (CpG sites,methylation of is,blood modification associated,1.0)]

[(circulating leukocyte DNA methylation patterns,differ by,race,1.0), (circulating leukocyte DNA methylation patterns,differ for,smoking dose,1.0), (leukocyte DNA methylation patterns,differ for,same smoking dose,1.0), (leukocyte DNA methylation patterns,differ by,race,1.0), (leukocyte DNA methylation patterns,differ for,smoking dose,1.0), (circulating leukocyte DNA methylation patterns,differ for,same smoking dose,1.0)]

Abstract 2

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 38 | Radiation, damage, tissues, tissues, irradiation, phenomenon, effects, Melatonin, antioxidant, agent, protection, tissues, irradiation, addition, studies, Melatonin, properties, mechanisms, effects, aim, study, effect, pretreatment, melatonin, damage, irradiation, bystander, effects, lung, heart, tissue, xenograft, mice, colon, cancer, irradiation, Balb/c, mice, |
| POS:Verb | 15 | causes, do, receive, called, is, known, ionizing, have, suggested, have, remain, act, was, evaluate, caused, |
| NER : Name | 0 |  |
| Triplet | 8 | Seen below |
|  |  |  |

[(tobacco use,is in,health care settings,1.0)]

[(few smokers,However receive,cessation advice,1.0), (smokers,visiting,hospital,1.0), (few smokers,visiting,hospital,1.0), (few smokers,receive,cessation advice,1.0), (smokers,However receive,cessation advice,1.0), (smokers,receive,cessation advice,1.0)]

[(could effective strategy,is with,potential expose,1.0)]

Abstract 3

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 11 | nequality, priority, governments, changes, crisis, study, causes, death, inequality, terms, Italy, |
| POS:Verb | 6 | Monitoring, has, become, followed, aimed, detecting, |
| NER : Name | 0 |  |
| Triplet | 39 | Seen below |
|  |  |  |

[(Lung cancer screening,reduce,specific mortality in populations,1.0), (Lung cancer screening,is with,annual low-dose computed tomography scans,1.0), (specific mortality,is in,selected populations,1.0), (Lung cancer screening,reduce,specific mortality,1.0), (Lung cancer screening,reduce,mortality,1.0), (annual low-dose computed tomography scans,with screening is,LCS,1.0), (Lung cancer screening,reduce,specific mortality in selected populations,1.0), (Lung cancer screening,reduce,mortality in populations,1.0), (Lung cancer screening,reduce,mortality in selected populations,1.0), (Lung cancer screening,has,has seen,1.0)]

[(participation,is key to,screening programs,1.0), (participation,is key to,successful screening programs,1.0), (participation,is,key,1.0), (participation,However is key to,successful screening programs,1.0), (participation,is,However key,1.0), (participation,However is key to,screening programs,1.0)]

[(EDIFICE nationwide surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE nationwide surveys,assess,behavior,1.0), (behavior,related to,cancer screening programs in France,0.586438403410859), (EDIFICE nationwide observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE nationwide observational surveys,assess,behavior related to cancer screening programs,1.0), (EDIFICE observational surveys,are,used,1.0), (behavior,related to,cancer screening programs,0.586438403410859), (EDIFICE observational surveys,assess,behavior related to cancer screening programs in France,1.0), (cancer screening programs,is in,France,1.0), (EDIFICE nationwide surveys,are,used,1.0), (EDIFICE nationwide surveys,assess,behavior related,1.0), (EDIFICE surveys,are,used,1.0), (EDIFICE surveys,assess,behavior,1.0), (EDIFICE observational surveys,assess,behavior,1.0), (EDIFICE nationwide observational surveys,are,used,1.0), (EDIFICE nationwide observational surveys,assess,behavior related,1.0), (EDIFICE surveys,assess,behavior related to cancer screening programs in France,1.0), (EDIFICE surveys,assess,behavior related,1.0), (EDIFICE observational surveys,assess,behavior related,1.0)]

Abstract 4

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 8 | study, trends, prevalence, asthma, decades, hospitalization, mortality, period, |
| POS:Verb | 1 | examines, |
| NER : Name | 0 |  |
| Triplet | 0 | Seen below |
| Medical Words: asthma Disease | 5 | … |
| Medical Words: Death Disease | 1 |  |
| Medical Words: women Species | 1 |  |
| Medical Words: asthmatic Disease | 8 |  |
| Medical Words: lung cancer Disease | 2 |  |
| … |  |  |

Abstract5:

count for POS\_noun is 105:

count for POS\_verb is 30:

count for NER\_name is 0:

Abstract 5

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 105 | relationship, mouse, minute, binding, protein, MTBP, prognosis, cancer, patients, reanalysis, observation, lung, adenocarcinoma, result, data, analysis.We, data, order, conclusion, relationship, MTBP, prognosis, cancer, patients, lung, cancer, patients, MTBP, information, results, data, analysis, GSE30219, Kaplan-Meier, curve, results, data, groups, Fig., Kaplan-Meier, curve, result, GSE16011, Fig., 1A, concordance, index, Log-Rank, Equal, Curves, P, 5.942e-05, R, risk, groups, hazard, ratio, conf, int, P, 7.344e-05, stratification, results, Figs., results, data, groups, tissue, sections, patients, lung, adenocarcinoma, expression, rate, MTBP, adenocarcinoma, %, results, patients, expression, MTBP, prognosis, control, group, survival, curves, 4B, P, expression, MTBP, event, survival, cancer, patients, glioblastoma, kidney, cancer, lung, cancer, patients, lung, cancer, patients, MTBP, status, |
| POS:Verb | 30 | explore, was, conducted, was, taken, verify, reanalyzed, downloaded, make, collected, verify, were, shown, was, shown, were, displayed, be, seen, were, collected, stained, was, showed, had, were, separated, has, been, verified, |
| NER : Name | 0 |  |
| Triplet | 81 | Seen below |
| Medical Words: MTBP Gene | 8 |  |
| Medical Words: malignant tumors Disease | 1 |  |
| Medical Words: mouse Species | 1 |  |
| Medical Words: cancer Disease | 3 |  |
| Medical Words: patients Species | 8 |  |
| Medical Words: lung adenocarcinoma Disease | 2 |  |
| Medical Words: lung cancer Disease | 3 |  |
| Medical Words: GSE30219 Chemical | 2 |  |
| Medical Words: adenocarcinoma Disease | 1 |  |
| Medical Words: glioblastoma Disease | 1 |  |
| Medical Words: kidney cancer Disease | 1 |  |
| … |  |  |

[(number,high prevalence in,Indonesia,0.9870394177331699), (number,prevalence of,smokers,0.9870394177331699), (high prevalence,is in,Indonesia,1.0), (number,prevalence in,Indonesia,0.9870394177331699), (number,high prevalence of,smokers,0.9870394177331699)]

[(Secondhand smoke,causes,health problems including cancer,1.0), (Secondhand smoke,causes,many health problems including cancer,1.0), (smoke,causes,health problems including cancer,1.0), (smoke,causes,many health problems including cancer,1.0)]

[(secondhand smoking,is in,Indonesia,1.0)]

[(research,was,epidemiological prevalence-based research design with cancers prevalence data,0.9472578451304835), (research,was,epidemiological prevalence-based research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,epidemiological prevalence-based research design with cancers prevalence data gained,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,prevalence-based research design with cancers prevalence data,0.9472578451304835), (research,was,research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,prevalence-based research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,usingdescriptive epidemiological research design,0.9472578451304835), (research,was,epidemiological research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,research design with cancers prevalence data gained,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design,0.9472578451304835), (research,was,prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,usingdescriptive epidemiological research design with cancers prevalence data,0.9472578451304835), (research,was,prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,usingdescriptive epidemiological prevalence-based research design with cancers prevalence data,0.9472578451304835), (research,was,usingdescriptive research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,epidemiological research design,0.9472578451304835), (research,was,usingdescriptive epidemiological prevalence-based research design,0.9472578451304835), (research,was,epidemiological prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,research design with cancers prevalence data,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design with cancers prevalence data,0.9472578451304835), (research,was,usingdescriptive research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,epidemiological prevalence-based research design,0.9472578451304835), (research,was,usingdescriptive epidemiological research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (usingdescriptive epidemiological prevalence-based research design,is with,cancers prevalence data gained from Indonesianhealth assurance system database in 2016,1.0), (research,was,usingdescriptive epidemiological prevalence-based research design with cancers prevalence data gained,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,epidemiological research design with cancers prevalence data,0.9472578451304835), (research,was,research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,usingdescriptive epidemiological research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,prevalence-based research design,0.9472578451304835), (research,was,research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,usingdescriptive prevalence-based research design with cancers prevalence data gained,0.9472578451304835), (cancers prevalence data,gained in,2016,0.6667396379761066), (cancers prevalence data,gained from,Indonesianhealth assurance system database,0.6667396379761066), (research,was,usingdescriptive research design with cancers prevalence data,0.9472578451304835), (research,was,usingdescriptive research design with cancers prevalence data gained,0.9472578451304835), (research,was,usingdescriptive epidemiological prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,usingdescriptive epidemiological research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,research design,0.9472578451304835), (research,was,usingdescriptive research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,prevalence-based research design with cancers prevalence data gained,0.9472578451304835), (research,was,epidemiological research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,usingdescriptive research design,0.9472578451304835), (research,was,usingdescriptive epidemiological prevalence-based research design with cancers prevalence data gained in 2016,0.9472578451304835), (research,was,epidemiological prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database in 2016,0.9472578451304835), (research,was,usingdescriptive epidemiological prevalence-based research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,epidemiological research design with cancers prevalence data gained,0.9472578451304835), (research,was,epidemiological research design with cancers prevalence data gained from Indonesianhealth assurance system database,0.9472578451304835), (research,was,usingdescriptive epidemiological research design with cancers prevalence data gained,0.9472578451304835)]

[(SAFs,combining,data of secondhand smokingprevalence,1.0), (SAFs,combining,DALY indicator,1.0), (calculated,is,calculated,1.0), (SAFs,combining,data of smokingprevalence,1.0), (SAFs,is,calculated,0.7989139425172863), (SAFs,combining,risk,1.0), (SAFs,combining,data,1.0), (SAFs,combining,relative risk,1.0)]

[]

[(burden priorities,were,lung cancer,1.0), (burden priorities,were,Meanwhile lung cancer,1.0)]

[(total,diseases to,due secondhand smoke analyzed in thisstudy,1.0), (283,360 DALYs,is In,total,1.0)]

[(results,can,can used as basis,1.0), (results,can,Thus can used as basis for policies,1.0), (results,can,can used as basis for policies,1.0), (results,can,Thus can used as basis for further policies,1.0), (results,can,can used as basis for further policies,1.0), (results,can,Thus can used as basis,1.0), (results,can,Thus can used,1.0), (results,can,can used,1.0)]

Abstract 6

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 41 | stage, c-stage, diagnosis, marker, patients, cancer, survival, rates, landmarks, outcomes, case, study, c-stage, lung, cancer, patients, candidates, therapy, year, diagnosis, cases, Cases, Lung, Cancer, Register, DLCR, records, treatment, details, cause, death, CoD, aims, clusters, patients, terms, CoD, treatment, modality, risk, outcome, |
| POS:Verb | 14 | is, assessing, is, were, considered, died, were, identified, were, used, retrieve, were, identify, describe, |
| NER : Name | 0 |  |
| Triplet | 23 | Seen below |
| Medical Words: Death Disease | 2 |  |
| Medical Words: stage I lung cancer Disease | 1 |  |
| Medical Words: patients Species | 8 |  |
| Medical Words: cancer Disease | 3 |  |
| Medical Words: c-stage I lung cancer Disease | 1 |  |
| Medical Words: CoD Gene | 5 |  |
| Medical Words: male Species | 3 |  |
| Medical Words: lung cancer Disease | 3 |  |
| … |  |  |

[]

[(other risks,include,occupational exposures,1.0), (risks,include,passive smoke inhalation,1.0), (other risks,include,passive smoke inhalation,1.0), (risks,include,radon,1.0), (other risks,include,smoke inhalation,1.0), (risks,include,exposures,1.0), (other risks,include,susceptibility,1.0), (other risks,include,infection,1.0), (risks,include,smoke inhalation,1.0), (other risks,include,genetic susceptibility,1.0), (risks,include,residential radon,1.0), (risks,include,occupational exposures,1.0), (risks,include,susceptibility,1.0), (other risks,include,exposures,1.0), (risks,include,infection,1.0), (other risks,include,radon,1.0), (other risks,include,residential radon,1.0), (risks,include,genetic susceptibility,1.0)]

[(disease burden,falls on,minority populations,1.0), (disease burden,currently falls on,minority populations,1.0), (predominant disease burden,currently falls on,minority populations,1.0), (predominant disease burden,falls on,minority populations,1.0)]

[(recreational use,is in,many states,1.0)]

Abstract7:

count for POS\_noun is 145:

count for POS\_verb is 49:

count for NER\_name is 1: BALF,

Abstract 7

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 145 | Lung, cancer, LC, causes, deaths, world, trace, elements, roles, process, reactions, metalloproteins, cofactors, study, lung, cancer, patients, controls, men, women, years, March, June, elements, study, V, Cr, Mn, Fe, Co, Cu, Zn, Se, Mo, Cd, Pb, V, Cd, Cr, Pb, others, Co, Mo, Se, Fe, Zn, ICP-QQQ-MS, serum, urine, time, lavage, fluid, BALF, order, involvement, metals, process, approach, precipitation, proteins, NDPP, fractionation, mass, HMM, mass, LMM, metal, species, order, metal, species, activity, potential, elements, work, NDPP, analysis, metals, ICP-QQQ-MS, time, serum, urine, BALF, samples, lung, cancer, patients, controls, order, molecule, profiles, MSMP, biomarkers, processes, stress, homeostasis, sense, metals, biomarkers, complexes, mass, ligands, form, metalloproteins, V, Cr, HMM, Cu, LMM, time, hand, metal, dyshomeostasis, biomarkers, ratios, correlations, ratios, elements, biomarkers, lung, cancer, serum, V/Mn, V/Pb, V/Zn, Cr/Pb, urine, Cr/Cd, Mn/Cd, V/Cd, Co/Cd, Cd/Pb, BALF, V/Cu, dyshomeostasis, metals, lung, cancer, sense, metals, others, existence, homeostasis, lung, cancer, |
| POS:Verb | 49 | is, is, known, play, activating, inhibiting, participate, was, conducted, have, been, included, considered, are, have, been, analyzed, understand, based, has, been, optimized, distinguish, affect, followed, has, been, applied, get, be, used, have, demonstrated, are, are, complexed, has, been, described, are, proposed, using, were, shown, be, reflects, are, correlated, suggesting, |
| NER : Name | 1 | BALF, |
| Triplet | 99 | seen below |
| Medical Words: Metal dyshomeostasis Disease | 1 |  |
| Medical Words: lung cancer Disease | 7 |  |
| Medical Words: human Species | 1 |  |
| Medical Words: LC Disease | 1 |  |
| Medical Words: cancer-related deaths Disease | 1 |  |
| Medical Words: patients Species | 2 |  |
| Medical Words: men Species | 1 |  |
| Medical Words: women Species | 1 |  |
| Medical Words: Cr Chemical | 5 |  |
| Medical Words: Mn Chemical | 3 |  |
| Medical Words: Fe Chemical | 2 |  |
| Medical Words: Cu Chemical | 3 |  |
| Medical Words: Zn Chemical | 3 |  |
| Medical Words: Se Chemical | 2 |  |
| Medical Words: Mo Chemical | 2 |  |
| Medical Words: Cd Chemical | 7 |  |
| Medical Words: Pb Chemical | 5 |  |
| Medical Words: MS Disease | 2 |  |
| Medical Words: non-denaturing precipitation of proteins Gene | 1 |  |
| Medical Words: NDPP Gene | 2 |  |
| Medical Words: V Chemical | 1 |  |
| … |  |  |

[(Lung cancer,is leading cause of,cancer death,1.0), (Lung cancer,be reduced through,targeted application,0.8420706941939625), (Lung cancer,be reduced through,targeted application of chemoprevention,0.8420706941939625), (Lung cancer,is,leading cause,1.0), (Lung cancer,be reduced through,application of chemoprevention,0.8420706941939625), (Lung cancer,is,cause,1.0), (Lung cancer,be,reduced,0.8420706941939625), (Lung cancer,be reduced through,application,0.8420706941939625), (Lung cancer,is cause of,cancer death,1.0)]

[(development,has,has linked,1.0), (development,has,has linked with high grade dysplasia,1.0), (development,has,has linked with persistent grade bronchial dysplasia,1.0), (development,has,has linked with persistent high grade bronchial dysplasia,1.0), (development,has,has linked with high grade bronchial dysplasia,1.0), (development,has,has linked with grade bronchial dysplasia,1.0), (development,has,has linked with grade dysplasia,1.0), (development,has,has linked with persistent grade dysplasia,1.0), (development,has,has linked with persistent high grade dysplasia,1.0)]

[(Bronchial histology,improved in,chemoprevention trial,1.0), (histology,improved in,chemoprevention trial,1.0), (histology,improved in,former smokers,1.0), (Bronchial histology,improved in,chemoprevention trial with prostacyclin analogue iloprost,1.0), (histology,improved in,chemoprevention trial with prostacyclin analogue iloprost,1.0), (chemoprevention trial,is with,prostacyclin analogue iloprost,1.0), (Bronchial histology,improved in,former smokers,1.0)]

[(Prostacyclin,acts through,peroxisome receptor gamma,1.0), (Prostacyclin,reverse,epithelial,1.0), (Prostacyclin,reverse,epithelial to transition,1.0), (epithelial,promote,signaling,1.0), (epithelial,promote,anti-cancer signaling,1.0), (Prostacyclin,acts through,peroxisome proliferator-activated receptor gamma,1.0), (Prostacyclin,acts through,PPARg,1.0), (Prostacyclin,reverse,epithelial to mesenchymal transition,1.0)]

[(EMT,provide,response markers for prostacyclin chemoprevention of lung cancer,1.0), (prostacyclin signaling pathway,provide,response markers for prostacyclin chemoprevention,1.0), (prostacyclin signaling pathway,provide,response markers for prostacyclin chemoprevention of lung cancer,1.0), (EMT,provide,response markers,1.0), (prostacyclin signaling pathway,provide,response markers,1.0), (EMT,provide,response markers for prostacyclin chemoprevention,1.0)]

[(RNA,was,extracted,1.0), (epithelial cells,were treated with,cigarette smoke condensate,1.0), (Human cells,were treated with,cigarette smoke condensate,1.0), (bronchial epithelial cells,were treated with,cigarette smoke condensate,1.0), (cells,CSC for,16 weeks,1.0), (epithelial cells,were,treated,1.0), (Human bronchial epithelial cells,were,treated,1.0), (bronchial epithelial cells,CSC for,16 weeks,1.0), (Human bronchial cells,were,treated,1.0), (Human epithelial cells,were,treated,1.0), (Human cells,CSC for,16 weeks,1.0), (Human epithelial cells,CSC for,16 weeks,1.0), (cells,were treated with,cigarette smoke condensate,1.0), (Human bronchial cells,were treated with,cigarette smoke condensate,1.0), (Human bronchial epithelial cells,CSC for,16 weeks,1.0), (epithelial cells,CSC for,16 weeks,1.0), (cells,were,treated,1.0), (bronchial epithelial cells,were,treated,1.0), (Human epithelial cells,were treated with,cigarette smoke condensate,1.0), (bronchial cells,were,treated,1.0), (bronchial cells,were treated with,cigarette smoke condensate,1.0), (Human cells,were,treated,1.0), (Human bronchial cells,CSC for,16 weeks,1.0), (Human bronchial epithelial cells,were treated with,cigarette smoke condensate,1.0), (bronchial cells,CSC for,16 weeks,1.0)]

[(Wild type,were,exposed to one week,1.0), (RNA,was,extracted,1.0), (Wild type,were,exposed to one week of cigarette smoke,1.0), (RNA,was extracted from,lungs,1.0), (Wild type,were,exposed,1.0)]

[(We,measured,potential markers of prostacyclin in models,1.0), (We,measured,potential markers of prostacyclin,1.0), (We,measured,potential markers in models,1.0), (potential markers,is in,models,1.0), (We,measured,potential markers,1.0)]

[(We,affected by,prostacyclin including PPARg,1.0), (We,affected by,prostacyclin,1.0), (We,inversely affected by,prostacyclin,1.0), (We,identified,panel,1.0), (We,inversely affected by,prostacyclin including PPARg,1.0)]

[(chemoprevention,is with,prostacyclin,1.0), (data,introduce,panel,1.0)]

[(Chemoprevention,is,promising,1.0)]

[(Identifying markers,is critical for,success in future trials,1.0), (markers,is critical for,success in future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (markers,is,critical,1.0), (markers,is critical for,success in future clinical trials,1.0), (Identifying markers,is critical for,success in future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is critical for,success in future clinical trials,1.0), (markers,is critical for,success,1.0), (Identifying markers,is critical for,success,1.0), (success,is in,future clinical trials of prostacyclin for lung cancer chemoprevention,1.0), (markers,is critical for,success in future trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is critical for,success in future clinical trials of prostacyclin,1.0), (markers,is critical for,success in future trials,1.0), (markers,is critical for,success in future clinical trials of prostacyclin,1.0), (Identifying markers,is critical for,success in future trials of prostacyclin for lung cancer chemoprevention,1.0), (Identifying markers,is,critical,1.0), (Identifying markers,is critical for,success in future trials of prostacyclin,1.0), (markers,is critical for,success in future trials of prostacyclin,1.0)]

Abstract 8

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 38 | complications, anomalies, malformations, syndrome, vessel, abnormalities, patients, telomere, biology, disorders, TBDs, care, consortium, ailments, family, group, Dyskeratosis, Congenita, Outreach, Inc., workshop, abnormalities, TBDs, National, Cancer, Institute, October, Clinicians, scientists, data, complications, hypotheses, biology, collaborations, etiology, management, complications, TBDs, |
| POS:Verb | 10 | bleeding, are, being, reported, described, support, held, reviewed, developed, address, |
| NER : Name | 0 | J |
| Triplet | 193 | Seen below |
| Medical Words: Vascular complications Disease | 4 |  |
| Medical Words: telomere biology disorders Disease | 2 |  |
| Medical Words: bleeding Disease | 1 |  |
| Medical Words: gastrointestinal telangiectatic anomalies Disease | 1 |  |
| Medical Words: pulmonary arteriovenous malformations Disease | 1 |  |
| Medical Words: hepatopulmonary syndrome Disease | 1 |  |
| Medical Words: retinal vessel abnormalities Disease | 1 |  |
| Medical Words: patients Species | 1 |  |
| Medical Words: TBDs Disease | 3 |  |
| Medical Words: vascular abnormalities Disease | 1 |  |
| Medical Words: Cancer Disease | 1 |  |
| … |  |  |

[(Chronic pulmonary disease,is,chronic inflammatory disorder,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (disease,is,disorder,1.0), (pulmonary disease,is,disorder,1.0), (Chronic disease,is chronic disorder with,incidence of lung cancer,1.0), (Chronic pulmonary disease,is chronic disorder with,incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic disease,is chronic disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is disorder with,increased incidence,1.0), (obstructive disease,is chronic disorder with,increased incidence,1.0), (disease,is,chronic disorder,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive disease,is,disorder,1.0), (disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic disease,is,disorder,1.0), (Chronic obstructive pulmonary disease,is disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,disorder,1.0), (disease,is disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,incidence,1.0), (obstructive disease,is chronic disorder with,incidence of lung cancer,1.0), (obstructive disease,is,inflammatory disorder,1.0), (Chronic obstructive disease,is disorder with,incidence,1.0), (obstructive disease,is disorder with,increased incidence,1.0), (pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is,chronic inflammatory disorder,1.0), (pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (chronic inflammatory disorder,is with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (obstructive disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,incidence,1.0), (disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is inflammatory disorder with,increased incidence,1.0), (obstructive pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic disorder with,increased incidence,1.0), (obstructive disease,is disorder with,incidence,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (obstructive disease,is,disorder,1.0), (Chronic pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is,chronic disorder,1.0), (obstructive pulmonary disease,is inflammatory disorder with,incidence,1.0), (pulmonary disease,is,inflammatory disorder,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,incidence,1.0), (Chronic disease,is disorder with,increased incidence of lung cancer,1.0), (disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is inflammatory disorder with,incidence,1.0), (obstructive disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is,chronic disorder,1.0), (Chronic obstructive pulmonary disease,is disorder with,incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive disease,is disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (Chronic disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is,disorder,1.0), (obstructive pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is disorder with,increased incidence,1.0), (Chronic disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic disorder with,increased incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic pulmonary disease,is,chronic disorder,1.0), (Chronic disease,is disorder with,incidence,1.0), (disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic disease,is inflammatory disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is disorder with,incidence of lung cancer,1.0), (disease,is disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,incidence,1.0), (Chronic pulmonary disease,is chronic disorder with,increased incidence,1.0), (obstructive pulmonary disease,is chronic disorder with,increased incidence,1.0), (Chronic pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (obstructive disease,is disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,incidence of lung cancer,1.0), (disease,is disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (disease,is,chronic,1.0), (Chronic obstructive disease,is chronic inflammatory disorder with,increased incidence,1.0), (pulmonary disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is,inflammatory disorder,1.0), (Chronic pulmonary disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic disorder with,incidence of lung cancer,1.0), (pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (disease,is disorder with,incidence,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is,inflammatory disorder,1.0), (Chronic disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,chronic disorder,1.0), (pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive pulmonary disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is chronic disorder with,incidence,1.0), (Chronic disease,is disorder with,incidence of lung cancer,1.0), (Chronic disease,is inflammatory disorder with,incidence,1.0), (obstructive pulmonary disease,is disorder with,incidence,1.0), (obstructive disease,is,chronic disorder,1.0), (Chronic disease,is disorder with,increased incidence,1.0), (Chronic obstructive disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is chronic disorder with,incidence,1.0), (pulmonary disease,is,chronic disorder,1.0), (disease,is inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (disease,is chronic disorder with,incidence,1.0), (pulmonary disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is disorder with,incidence of lung cancer,1.0), (obstructive disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is disorder with,incidence,1.0), (pulmonary disease,is,chronic inflammatory disorder,1.0), (Chronic pulmonary disease,is,disorder,1.0), (obstructive pulmonary disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic pulmonary disease,is disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (obstructive pulmonary disease,is,chronic disorder,1.0), (Chronic obstructive disease,is chronic disorder with,increased incidence,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,increased incidence,1.0), (Chronic pulmonary disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (Chronic pulmonary disease,is disorder with,increased incidence,1.0), (obstructive pulmonary disease,is,chronic inflammatory disorder,1.0), (disease,is inflammatory disorder with,incidence,1.0), (Chronic disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic disease,is chronic disorder with,increased incidence,1.0), (obstructive disease,is inflammatory disorder with,increased incidence of lung cancer,1.0), (pulmonary disease,is disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is inflammatory disorder with,incidence of lung cancer,1.0), (Chronic obstructive pulmonary disease,is,inflammatory disorder,1.0), (pulmonary disease,is chronic disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is,chronic inflammatory disorder,1.0), (disease,is,inflammatory,1.0), (disease,is,chronic inflammatory disorder,1.0), (obstructive disease,is chronic disorder with,increased incidence of lung cancer,1.0), (obstructive disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic obstructive disease,is inflammatory disorder with,increased incidence,1.0), (Chronic obstructive disease,is chronic disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,incidence of lung cancer,1.0), (disease,is chronic inflammatory disorder with,increased incidence of lung cancer,1.0), (Chronic disease,is chronic inflammatory disorder with,increased incidence,1.0), (obstructive disease,is chronic inflammatory disorder with,incidence,1.0), (Chronic obstructive pulmonary disease,is chronic disorder with,increased incidence,1.0)]

[(emphysema component,confers,greatest proportion,1.0), (emphysema component,confers,proportion to lung cancer risk,1.0), (emphysema component,confers,proportion,1.0), (emphysema component,confers,greatest proportion to lung cancer risk,1.0)]

[(tumors,escape,immunity,1.0), (tumors,create,inflammatory conditions,1.0), (growth,is in,pre-established inflammatory microenvironments,1.0), (tumors,create,conditions,1.0)]

[(we,implanting cancer cells in,lungs of mice,1.0), (mice,is with,cigarette smoke-induced emphysema,1.0), (we,addressed issue In,study,1.0), (we,implanting,OVA-expressing cancer cells,1.0), (we,implanting cancer cells in,lungs,1.0), (we,implanting,cancer cells,1.0), (we,implanting cancer cells in,lungs of mice with cigarette emphysema,1.0), (we,addressed,issue,1.0), (we,implanting cancer cells in,lungs of mice with cigarette smoke-induced emphysema,1.0)]

[(Emphysema,augmented,growth of cancer cells,1.0), (Emphysema,augmented,growth,1.0)]

[(adoptive transfer,restore,their antitumor activity,1.0), (OVA-specific OTI T cells,showed,signs,1.0), (OVA-specific OTI T cells,showed,early signs of exhaustion,1.0), (OTI T cells,showed,signs,1.0), (OVA-specific OTI T cells,showed,signs of exhaustion,1.0), (OTI T cells,showed,early signs,1.0), (transfer,restore,their antitumor activity,1.0), (OTI T cells,showed,signs of exhaustion,1.0), (OTI T cells,showed,early signs of exhaustion,1.0), (transfer,is in,emphysema tumor hosts,1.0), (OVA-specific OTI T cells,showed,early signs,1.0)]

[]

Abstract 9

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 71 | hypertension, PH, disorder, increase, pressure, conditions, etiology, PH, impact, exercise, capacity, quality, life, mortality, hypertension, imaging, techniques, role, presence, PH, pressure, measurements, group, PH, disease, information, response, treatment, echocardiography, tomography, CT, ventilation/perfusion, scans, part, work-up, patients, PH, guidelines, centers, techniques, applications, field, PH, 3D, echocardiography, CT, 4D, flow, resonance, imaging, MRI, T1, volume, fraction, mapping, MRI, sequences, perfusion, ventilation, assessment, positron, emission, tomography, review, imaging, techniques, diagnosis, evaluation, follow-up, patients, PH., |
| POS:Verb | 22 | is, defined, occur, entails, is, associated, play, suggesting, providing, classifying, identifying, underlying, providing, assessing, computed, are, suspected, according, are, emerging, discusses, emerging, |
| NER : Name | 0 |  |
| Triplet | 108 | Seen below |
| … |  |  |

[(Cigarette smoke,is,major risk factor for development,1.0), (smoke,is,major,1.0), (Cigarette smoke,is,risk factor for development of lung cancer,1.0), (Cigarette smoke,is,major risk factor,1.0), (Cigarette smoke,is,major risk factor for development of lung cancer,1.0), (Cigarette smoke,is,risk factor,1.0), (Cigarette smoke,is,risk factor for development,1.0)]

[(transition,is,found,1.0), (Epithelial-mesenchymal transition,is found in,invasive phenotypes,1.0), (Epithelial-mesenchymal transition,is,found,1.0), (transition,is found in,phenotypes,1.0), (transition,is found in,phenotypes in lung cancer,1.0), (Epithelial-mesenchymal transition,is found in,phenotypes,1.0), (Epithelial-mesenchymal transition,is found in,invasive phenotypes in lung cancer,1.0), (transition,is found in,invasive phenotypes,1.0), (invasive phenotypes,is in,lung cancer,1.0), (transition,is found in,invasive phenotypes in lung cancer,1.0), (Epithelial-mesenchymal transition,is found in,phenotypes in lung cancer,1.0)]

[(MK-2206,administered alone at,doses,1.0), (MK-2206,administered at,tolerated doses,1.0), (MK-2206,administered at,doses,1.0), (MK-2206,administered alone at,tolerated doses,1.0)]

[(we,investigated,mechanism of MK-2206 in CS-induced pulmonary EMT and in vitro,1.0), (we,investigated,working mechanism in pulmonary EMT and in vitro,1.0), (we,investigated,mechanism in EMT,1.0), (we,investigated,mechanism in CS-induced EMT in vivo and,1.0), (we,investigated,mechanism in EMT and in vitro,1.0), (we,investigated,mechanism in EMT and,1.0), (we,investigated,working mechanism in pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism in pulmonary EMT and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced EMT in vivo and in vitro,1.0), (we,investigated,working mechanism in CS-induced EMT in vivo and,1.0), (we,investigated,working mechanism in EMT,1.0), (we,investigated,working mechanism of MK-2206 in pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism in CS-induced EMT and,1.0), (we,investigated,working mechanism of MK-2206,1.0), (we,investigated,working mechanism in CS-induced EMT,1.0), (we,investigated,mechanism of MK-2206 in EMT in vivo and in vitro,1.0), (we,investigated,mechanism in CS-induced EMT in vivo and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced EMT in vivo and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced pulmonary EMT and in vitro,1.0), (we,investigated,working mechanism in CS-induced pulmonary EMT in vivo and,1.0), (we,investigated,mechanism of MK-2206 in EMT,1.0), (we,investigated,working mechanism in CS-induced EMT and,1.0), (we,investigated,working mechanism of MK-2206 in pulmonary EMT and in vitro,1.0), (we,investigated,mechanism in CS-induced pulmonary EMT,1.0), (we,investigated,mechanism in CS-induced EMT and in vitro,1.0), (we,investigated,working mechanism of MK-2206 in pulmonary EMT and,1.0), (we,investigated,working mechanism in pulmonary EMT and,1.0), (we,investigated,mechanism of MK-2206 in CS-induced EMT and in vitro,1.0), (we,investigated,mechanism,1.0), (we,investigated,working mechanism in EMT in vivo and in vitro,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced EMT in vivo and,1.0), (we,investigated,working mechanism in EMT in vivo and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced EMT in vivo and in vitro,1.0), (we,investigated,working mechanism in CS-induced pulmonary EMT and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced EMT,1.0), (we,investigated,mechanism in CS-induced pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism of MK-2206 in pulmonary EMT,1.0), (we,investigated,working mechanism of MK-2206 in EMT in vivo and in vitro,1.0), (we,investigated,mechanism in CS-induced pulmonary EMT and in vitro,1.0), (we,investigated,working mechanism in CS-induced EMT in vivo and in vitro,1.0), (we,investigated,working mechanism of MK-2206 in EMT,1.0), (we,investigated,mechanism of MK-2206 in pulmonary EMT and,1.0), (working mechanism,is in,CS-induced pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism in EMT in vivo and,1.0), (we,investigated,working mechanism in EMT and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced pulmonary EMT,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced pulmonary EMT,1.0), (we,investigated,mechanism in pulmonary EMT in vivo and in vitro,1.0), (we,investigated mechanism In,study,1.0), (we,investigated,working mechanism in EMT and,1.0), (we,investigated,working mechanism in CS-induced pulmonary EMT,1.0), (we,investigated,mechanism of MK-2206 in CS-induced pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced pulmonary EMT in vivo and,1.0), (we,investigated,mechanism of MK-2206 in EMT and in vitro,1.0), (we,investigated,mechanism in pulmonary EMT and,1.0), (we,investigated,mechanism of MK-2206 in CS-induced pulmonary EMT and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced EMT and,1.0), (we,investigated,mechanism of MK-2206 in pulmonary EMT in vivo and in vitro,1.0), (we,investigated,mechanism of MK-2206 in CS-induced EMT and,1.0), (we,investigated,working mechanism of MK-2206 in EMT in vivo and,1.0), (we,investigated,working mechanism in CS-induced pulmonary EMT and,1.0), (we,investigated,mechanism in CS-induced EMT,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced pulmonary EMT and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced pulmonary EMT in vivo and,1.0), (we,investigated,mechanism of MK-2206 in pulmonary EMT in vivo and,1.0), (we,investigated,working mechanism of MK-2206 in pulmonary EMT in vivo and,1.0), (we,investigated,mechanism in pulmonary EMT in vivo and,1.0), (we,investigated,mechanism of MK-2206 in pulmonary EMT and in vitro,1.0), (we,investigated,working mechanism in pulmonary EMT in vivo and,1.0), (we,investigated,mechanism in CS-induced pulmonary EMT and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced EMT,1.0), (we,investigated,working mechanism in CS-induced EMT and in vitro,1.0), (we,investigated,working mechanism,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced pulmonary EMT in vivo and in vitro,1.0), (we,investigated,working mechanism of MK-2206 in EMT and in vitro,1.0), (we,investigated,mechanism in EMT in vivo and in vitro,1.0), (we,investigated,working mechanism in CS-induced pulmonary EMT in vivo and in vitro,1.0), (we,investigated,working mechanism in pulmonary EMT,1.0), (we,investigated,working mechanism of MK-2206 in EMT and,1.0), (we,investigated,mechanism of MK-2206,1.0), (we,investigated,mechanism of MK-2206 in EMT and,1.0), (we,investigated,working mechanism of MK-2206 in pulmonary EMT,1.0), (we,investigated,mechanism of MK-2206 in EMT in vivo and,1.0), (we,investigated,mechanism in CS-induced pulmonary EMT in vivo and,1.0), (we,investigated,working mechanism of MK-2206 in CS-induced EMT and in vitro,1.0), (we,investigated,mechanism in pulmonary EMT,1.0)]

Abstract 10

|  |  |  |
| --- | --- | --- |
| Type | Count | Examples ( Even List all words Depending on the Size) |
| POS : Noun | 68 | Anoikis, form, apoptosis, cell, detachment, Integrin, inactivation, role, process, signalling, pathway, anoikis, pathway, gliotoxin, GT, virulence, factor, fungus, Aspergillus, fumigatus, aspergillosis, humans, GT, integrin, binding, matrix, components, cysteines, binding, pocket, consequence, adhesion, kinase, FAK, dephosphorylation, p190RhoGAP, activation, RhoA, activation, ROCK, MKK4/MKK7, JNK, phosphorylation, Bim, Cells, suspension, integrin, surface, expression, GT, ROCK-MKK4, anoikis, attachment, fibronectin, integrin, upregulation, signalling, pathway, FAK, inhibition, integrin, αV/β3, Cilengitide, GT, integrins, anoikis, lung, cells, |
| POS:Verb | 23 | is, induced, plays, is, identify, using, causes, prevents, modifying, is, inhibited, resulting, allowing, triggers, lacking, are, are, sensitised, is, triggered, inhibiting, target, induce, |
| NER : Name | 0 |  |
| Triplet | 34 | John,was playing with,dog |
| Medical Words: fungal Species | 1 |  |
| Medical Words: Aspergillus fumigatus Species | 1 |  |
| Medical Words: invasive aspergillosis Disease | 1 |  |
| Medical Words: humans Species | 1 |  |
| Medical Words: cysteines Chemical | 1 |  |
| Medical Words: Cilengitide Chemical | 1 |  |
| … |  |  |

[(transition,is,step,1.0), (Epithelial-to-mesenchymal transition,is,step,1.0), (Epithelial-to-mesenchymal transition,is,initial step,1.0), (transition,is,initial step,1.0)]

[(widespread use,is,risk factor,1.0), (use,is still,major risk factor,1.0), (use,is still,risk factor for lung cancer,1.0), (widespread use,is still,risk factor for lung cancer,1.0), (widespread use,is,major risk factor,1.0), (use,is,risk factor for lung cancer,1.0), (use,is still,major risk factor for lung cancer,1.0), (widespread use,is,major risk factor for lung cancer,1.0), (widespread use,is still,major risk factor for lung cancer,1.0), (use,is,risk factor,1.0), (widespread use,is still,major risk factor,1.0), (smoking,is,risk factor,1.0), (smoking,is,major risk factor,1.0), (use,is,major risk factor,1.0), (use,is still,risk factor,1.0), (widespread use,is,risk factor for lung cancer,1.0), (smoking,is,major risk factor for lung cancer,1.0), (use,is,major risk factor for lung cancer,1.0), (smoking,is,risk factor for lung cancer,1.0), (smoking,is,major,1.0), (widespread use,is still,risk factor,1.0)]

[(lower levels,provide,safer alternative,1.0), (tobacco industry,has,Recently has transformed by introduction,1.0), (tobacco industry,has,has transformed,1.0), (lower levels,provide,alternative,1.0), (levels,provide,alternative,1.0), (levels,provide,safer alternative,1.0), (tobacco industry,has,Recently has transformed,1.0), (tobacco industry,has,has transformed by introduction,1.0)]

[(EMT,is in,A549 lung cancer cells,1.0)]